This review article discusses the historical origin of our continuously evolving model of the etiology of atherosclerotic cardiovascular disease. The basic molecular biologic concepts underlying the development of coronary artery disease and the dynamic connection between the immune system and arterial integrity are explored. Emphasis is placed on the role of inflammation as a driving force in the process of atherosclerosis and vascular endothelium as a modulating factor in the pathogenesis of coronary artery disease.
RossR.The pathogenesis of atherosclerosis—an update. N Engl J Med1986;314:488–500.
2.
DaviesMJ, GordonJL, GearingAJH, . The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol1993;171:223–9.
3.
DavidsonMH, MakiKC, PearsonTA, . Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol2005;96:556–63.
4.
StaryHC, ChandlerAB, GlagovS, . A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation1994;89:2462–78.
5.
LibbyP.Inflammation in atherosclerosis. Nature2002;420:868–74.
6.
LaRosaJC.Understanding risk in hypercholesterolemia. Clin Cardiol2003;26(1Suppl 1):3–6.
7.
GrundySM, BilheimerD, BlackburnH, . Rationale for the diet-heart statement of the American Heart Association. Circulation1982;65839A-54A.
8.
CleemanJI, LenfantC.The National Cholesterol Education Program: progress and prospects. JAMA1998;280:2099–104.
9.
RidkerPM.Evaluating novel cardiovascular risk factors: can we better predict heart attacks?Ann Intern Med1999;130:933–7.
10.
KinosianB, GlickH, GarlandG.Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med1994;121:641–7.
11.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation1994;89:1329–445.
12.
HavelRJ.Biology of cholesterol, lipoproteins and atherosclerosis. Clin Exp Hypertens1989;11:887–900.
13.
CastelliWP, GarrisonRJ, WilsonPW, . Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA1986;256:2835–8.
14.
GordonDJ, ProbstfieldJL, GarnsonRJ, . High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation1989;79:8–15.
15.
FieldingCJ.Lipoprotein receptors, plasma cholesterol metabolism, and the regulation of cellular free cholesterol concentration. FASEB J1992;6:3162–8.
16.
BallantyneCM, HerdA, FerlicLL, . Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation1999;99:736–43.
TurleySD.Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol2004;27(6Suppl 3):III16–21.
19.
RussellDW.The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem2003;72:137–74.
20.
van MilSW, HouwenRH, KlompLW.Genetics of familial intrahepatic cholestasis syndromes. J Med Genet2005;42:449–63.
21.
RosensonRS.Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis2004;173:1–12.
22.
VaughanC, GottoA, BassonC.The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol2000;35:1–10.
23.
StollL, McCormickM, DenningG, WeintraubN.Antioxidant effect of statins. Drugs Today2004;40:975–90.
24.
BraunwaldE.Shattuck Lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med1997;337:1360–9.
25.
van OostromAJ, van WijkJ, CabezasMC.Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs2004;64Suppl 2:19–41.
26.
DaughertyA, WebbNR, RateriDL, KingVL.Thematic review series: the immune system and atherogenesis. Cytokine regulation of macrophage functions in atherogenesis. J Lipid Res2005;46:1812–22.
27.
WardMM.Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum1999;42:338–46.
SaadeddinSM, HabbabMA, FernsGA.Markers of inflammation and coronary artery disease. Med Sci Monit2002;8RA5–12.
30.
NelkenNA, CoughlinSR, GordonD, WilcoxJN.Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest1991;88:1121–7.
31.
JonassonL, HolmJ, SkalliO, . Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis1986;6:131–8.
32.
StemmeS, FaberB, HolmJ, . T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A1995;92:3893–7.
33.
ZhouX, NicolettiA, ElhageR, HanssonGK.Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation2000;102:2919–22.
34.
HanssonGK, HolmJ, JonassonL.Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol1989;135:169–75.
35.
GengYJ, HolmJ, NygrenS, . Expression of macrophage scavenger receptor in atherosclerosis: relationship between scavenger receptor isoforms and the T cell cytokine, interferon-gamma. Arterioscler Thromb Vasc Biol1995;15:1995–2002.
JonassonGK, HolmJ, SkalliO, . Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest1985;76:125–31.
38.
LiH, FreemanMW,LibbyP.Regulation of smooth muscle cells scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest1995;95:122–33.
39.
GuptaS, PabloAM, JiangX, . Interferon-gamma potentiates atherosclerosis in apo E knock-out mice. J Clin Invest1997;99:2752–61.
40.
WhitmanSC, RavisankarP, ElamH, DaughertyA.Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E−/− mice. Am J Pathol2000;157:1819–24.
41.
AnderssonS, DavisDL, DahlbackH, . Cloning, structure and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem1989;264:8222–9.
42.
ReissAB, MartinKO, JavittNB, . Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res1994;35:1026–30.
43.
BjorkhemI, AnderssonO, DiczfalusyU, . Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A1994;91:8592–6.
44.
LundE, AnderssonO, ZhangJ, . Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol1996;16:208–12.
45.
BabikerA, DzeletovicS, WiklundB, . Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest2005;65:365–75.
46.
BabikerA, AnderssonO, LundE, . Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. J Biol Chem1997;266:7779–83.
47.
ReissAB, MartinKO, RojerDE, . Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res1997;38:1254–60.
48.
ReissAB, AwadallahNW, CronsteinBN.Cytochrome P450 cholesterol 27-hydroxylase: an anti-atherogenic enzyme. Recent Res Dev Lipids Res2000;4:39–50.
49.
BabikerA, DiczfalusyU.Transport of side-chain oxidized oxysterols in the human circulation. Biochim Biophys Acta1998;1392:333–9.
50.
JavittNB.26-Hydroxycholesterol: synthesis, metabolism and biologic activities. J Lipid Res1997;31:1527–33.
51.
EstermanAL, BaumH, JavittNB, DarlingtonGJ.26-Hydroxycholesterol: regulation of hydroxymethylglutaryl-CoA reductase activity in Chinese hamster ovary cell culture. J Lipid Res1983;24:1304–9.
52.
CorsiniA, VerriD, RaiteriM, . Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol1995;15:420–8.
53.
HultenLM, LindmarkH, DiczfalusyU, . Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J Clin Invest1996;97:461–8.
54.
KuriyamaM, FujiyamaJ, YoshidomeH, . Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients with review of the literature. J Neurol Sci1991;102:225–32.
KuriyamaM, TokimuraY, FujiyamaJ, . Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci1991;125:22–8.
59.
VerripsA, HoefslootLH, SteenbergenGC, . Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain2000;123:908–19.
60.
RosenH, ReshefA, MaedaN, . Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted 27-hydroxylase gene. J Biol Chem1998;273:14805–12.
61.
DubracS, LearSR, AnanthanarayananM, . Role of CYP27A in cholesterol and bile acid metabolism. J Lipid Res2005;46:76–85.
62.
LangmannT, KluckenJ, ReilM, . Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun1999;257:29–33.
63.
RustS, RosierM, FunkeH, . Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet1999;22:352–5.
64.
WalterM, GerdesU, SeedorfU, AssmannG.The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biophys Res Commun1994;205:850–6.
65.
SchwartzK, LawnRM, WadeDP.ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun2000;274:794–802.
66.
LehmannJM, KliewerSA, MooreLB, . Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem1997;272:3137–40.
67.
CostetP, LuoY, WangN, TallAR.Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem2000;275:28240–5.
68.
FuX, MenkeJG, ChenY, . 27-Hydroxycholesterol is an endogenous ligand for LXR in cholesterol-loaded cells. J Biol Chem2001;276:38378–87.
69.
ReissAB, AwadallahNW, MalhotraS, . Immune complexes and interferon-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res2001;42:1913–22.
70.
ReissAB, Rahman ChanESL, . Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leukoc Biol2004;76:727–34.
ChoiHK, HernanMA, SeegerJD, . Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet2002;359:1173–7.
73.
CronsteinBN, NaimeD, OstadE.The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol1994;370:411–6.
74.
ChenM, KakutaniM, MinamiM, . Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol2000;20:1107–15.
75.
RaderDJ, DugiKA.The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost2000;26:521–8.
76.
CominaciniL, PasiniAF, GarbinU, . Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem2000;275:12633–8.
77.
KumeN, MuraseT, MoriwakiH, . Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res1998;83:322–7.
78.
GeorgeJ, HaratsD, ShoenfeldY.Autoimmunity in atherosclerosis. The role of autoantigens. Clin Rev Allergy Immunol2000;18:73–86.
79.
HanssonM, WikvallK, BabikerA.Regulation of sterol 27-hydroxylase in human monocyte-derived macrophages: up-regulation by transforming growth factor beta1. Biochim Biophys Acta2005;1687:44–51.
80.
GraingerDJ, KempPR, MetcalfeJC, . The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med1995;1:74–9.
81.
AndreakosE, FoxwellB, FeldmannM.Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?Immunol Rev2004;202:250–65.
82.
TakedoK, KaishoT, AkiraS.Toll-like receptors. Annu Rev Immunol2003;21:335–76.
83.
ToshchakovV, JonesBW, PereraPY, . TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol2002;3:392–8.
84.
ZughaierSM, ZimmerSM, DattaA, . Differential induction of the Toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immun2005;73:2940–50.
85.
HornungV, RothenfusserS, BritschS, . Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol2002;168:4531–7.
86.
FaureE, EquilsO, SielingPA, . Bacterial lipopolysaccharide activates NF-kappaB through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem2000;275:11058–63.
87.
KiechlS, LorenzE, ReindlM, . Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med2002;347:185–92.
88.
XuXH, ShahPK, FaureE, . Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation2001;104:3103–8.
89.
EdfeldtK, SwedenborgJ, HanssonGK, YanZQ.Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation2002;105:1158–61.
90.
MonacoC, AndreakosE, KiriakidisS, . Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A2004;101:5634–9.
91.
CastrilloA, JosephSB, VaidyaSA, . Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell2003;12:805–16.
